Scanning optimization and evaluation of aging effect of dopamine transporter ligand [C-11]PE2I

Scanning optimization and evaluation of aging effect of dopamine transporter ligand [C-11]PE2I - Scanning optimization and aging effect of DAT PET with [C-11]PE2I

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013339

Enrollment

Registered

2014-03-05

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

The dosage in the vein of [C-11]PE2I for PET/CT imaging

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The subjects who has intention to participate in this study, and signed informed consent. 2. Male and female subjects of >=20 and =<80 years, old. 3. The subject who was judged by clinical investigator by means of physical examination and laboratory tests to be eligible as a participant in this study.

Exclusion criteria

Exclusion criteria: 1.The subject who has dysfunction in the liver / kidney. 2.The subject who has abnormal findings in the central nervous system. 3.The subjects having cardiac failure. 4.The subject with a history of a drug or food allergy. 5.Tobacco smoker 6.Pregnant or woman who has a chance of pregnant. 7.The subject who was judged by the clinical investigator to be inappropriate as a participant in this study.

Design outcomes

Primary

Measure	Time frame
Binding potential and tissue concentration ratio	—

Countries

Japan

Contacts

Public ContactKenji Ishii

Tokyo Metropolitan Institute of Geriatrics and Gerontology Research Team for Neuroimaging

ishii@pet.tmig.or.jp+81-3-3964-3241

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026